Comparison of Dexlansoprazole-based Triple and Rabeprazole-based Triple Therapies for Helicobacter Pylori Infection

• Status: Completed
• Trial end date: 2015-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Dexlansoprazole MR is the R-enantiomer of lansoprazole that is delivered by a dual delayed release formulation. It is effective for symptom control of patients with gastroesophageal reflux disease. However, its efficacy in the treatment of H.pylori infection remains unclear. This study was conducted to investigate whether the efficacy of single-dose dexlansoprazole MR-based triple therapy was non-inferior to double-dose rabeprazole-based triple therapy in the treatment of H.pylori infection.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kaohsiung Medical University
• Treatments: Amoxicillin; Clarithromycin; Dexlansoprazole; Lansoprazole; Rabeprazole

Criteria

Inclusion Criteria:

1. Male or non-pregnant female aged more than 20 years.

2. H. pylori-infected outpatients

3. Mental and legal ability to give a written informed consent.

Exclusion Criteria:

1. previous H pylori-eradication therapy,

2. ingestion of antibiotics or bismuth within the prior 4 weeks,

3. patients with allergic history to the medications used,

4. patients with previous gastric surgery,

5. the coexistence of serious concomitant illness (for example, decompensated liver cirrhosis, uremia),

6. pregnant women.